1 May 2011AmericasKatie Wang

Attacking the validity of selection patents

The conclusion is not surprising: a selection patent will not receive special treatment. Its validity is vulnerable to attack on any of the grounds provided in the Patent Act. Accordingly, a determination that the conditions for a select patent have not been met does not constitute an independent basis upon which to attack the validity of the patent (Eli Lilly Canada Inc. v Novopharm Limited).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.
Americas
19 January 2026   An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.
Americas
15 January 2026   The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.